104294-60-2

Upstream product

• 19798-94-8 6-methyl-6-phenyl-[1,3]oxazinane 
• 50-00-0 formaldehyd 
• 98-83-9 isopropenylbenzene 
• 98-86-2 acetophenone 
• 14368-31-1 3-hydroxy-3-phenylbutanenitrile 
• 1076160-14-9 C₁₀H₁₃N₃O 

Downstream Products

• 129906-63-4 3-phenyl-2-buten-1-amine 
• 1114064-30-0 4-(2-chloropyrimidin-4-ylamino)-2-phenylbutan-2-ol 
• 1114064-31-1 4-(4-chloropyrimidin-2-ylamino)-2-phenylbutan-2-ol 
• 1114064-48-0 6-methyl-6-phenyl-1,3-oxazinan-2-one 
• 1114065-24-5 2-phenyl-4-(4-phenylthiazol-2-ylamino)butan-2-ol 
• 1114064-50-4 3-(4-bromobenzyl)-6-methyl-6-phenyl-1,3-oxazinan-2-one 
• 1076160-17-2 C₁₅H₂₄N₂OS 
• 38135-56-7 (3-phenyl-n-butyl)-amine 

Relevant academic research and scientific papers

Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11β-hydroxysteroid dehydrogenase type 1

Structure based design led directly to 1,3-oxazinan-2-one 9a with an IC50 of 42 nM against 11β-HSD1 in vitro. Optimization of 9a for improved in vitro enzymatic and cellular potency afforded 25f with IC 50 values of 0.8 nM for the enzyme and 2.5 nM in adipocytes. In addition, 25f has 94% oral bioavailability in rat and >1000× selectivity over 11β-HSD2. In mice, 25f was distributed to the target tissues, liver, and adipose, and in cynomolgus monkeys a 10 mg/kg oral dose reduced cortisol production by 85% following a cortisone challenge.

PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ALZHEIMER'S DISEASE

A pharmaceutical composition for treating Alzheimer's disease containing a compound represented by the general formula (I): wherein ring A is an optionally substituted carbocyclic group or an optionally substituted heterocyclic group; E is lower alkylene,

CYCLIC INHIBITORS OF 11β-HYDROXYSTERIOD DEHYDROGENASE 1

This invention relates to novel compounds of the Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih); (Ii); (Ij), (Ik), (II) pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.

AMINODIHYDROTHIAZINE DERIVATIVE

A composition having BACE 1 inhibitory activity containing a compound represented by the general formula (I): wherein ring A is an optionally substituted carbocyclic group or an optionally substituted heterocyclic group; E is lower alkylene; X is S, O, or NR1; R1 is a hydrogen atom or lower alkyl; R2a, R2b, R3a, R3b, R4a and R4b is each independently a hydrogen atom, halogen, or hydroxy etc.; n and m are each independently an integer of 0 to 3; n+m is an integer of 0 to 3; R5 is a hydrogen atom or substituted lower alkyl; its pharmaceutically acceptable salt, or a solvate thereof